XERIS BIOPHARMA HOLDINGS INC (XERS)

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference

XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023

XERS stock results show that Xeris Biopharma Holdings met analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.

XERS Stock Earnings: Xeris Biopharma Holdings Meets EPS, Beats Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Xeris Biopharma Holdings (NASDAQ:XERS) just reported results for the fourth qua...

Xeris Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Events

Xeris Refinances Its $150M Senior Secured Term Loan Facility With Hayfin Capital

Xeris Biopharma to Report Fourth Quarter and Full Year 2023 Financial Results on March 6, 2024

Insiders Were Right: XERS Makes New 52-Week High

Commit To Purchase Xeris Biopharma Holdings At $2.50, Earn 20.7% Annualized Using Options

Xeris to Present at the Oppenheimer 34th Annual Healthcare Life Science Conference

Morgan Stanley Block Sale Sends Chewy (CHWY) Stock Down

Chewy stock is falling on Wednesday after it was announced that Morgan Stanley is handling a block sale of CHWY shares.

Why Is Xeris Biopharma (XERS) Stock Up 12% Today?

Xeris Biopharma stock is rising higher on Wednesday as investors in XERS shares react to a new exclusive worldwide license agreement.

Amgen joins Xeris Biopharma for Tepezza version (NASDAQ:AMGN)

Xeris Biopharma (XERS) stock gains after the company joined Amgen (AMGN) for a subcutaneous version of the thyroid eye disease therapy, Tepezza. Read more here.

Xeris Biopharma Enters Into an Exclusive Worldwide License Agreement for Xeriject® Formulation of Teprotumumab

7 Small-Cap Stocks to Best Position Your Portfolio for a Strong 2024

Small cap stocks are anticipated to rise by as much as 50% in 2024 as investors look for growth in new areas of the market.

Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma sees FY revenue at higher end of guidance (NASDAQ:XERS)

Xeris Biopharma Holdings expects higher revenue, positive cashflow, and increased cash reserves in Q4.

Xeris Biopharma Updates Its Outlook for 2023

Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Xeris Biopharma Reports Third Quarter 2023 Financial Results

Commit To Purchase Xeris Biopharma Holdings At $1.50, Earn 16.9% Annualized Using Options

Xeris Biopharma Raises Full-Year Financial Guidance and Reaffirms Cash Flow Breakeven in Q4 2023

Xeris Biopharma Announces Private Convertible Note Exchange Transactions

Xeris to Participate in the 2023 Cantor Global Healthcare Conference

Xeris to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

Xeris Pharmaceuticals reports Q2 revenue (NASDAQ:XERS)

Xeris Pharmaceuticals press release (XERS): Q2 revenue of $38M (+50.1% Y/Y) misses by $2.93M.